|Bid||135.45 x 1100|
|Ask||136.00 x 1000|
|Day's Range||131.39 - 144.77|
|52 Week Range||119.01 - 497.49|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||8.16|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||230.27|
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) are no longer big winners for investors. Let's first address the uncertainties for Moderna. There are questions about the high number of side effects of its experimental influenza vaccine.
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.